Measurements of quality of life in patients needing palliative care are too complex, have poor relevance to patient needs and perceptions, and are difficult to administer in practice, say Drs Feinberg and Kiss. They believe that some currently available quality-of-life instruments have applicability to the palliative care setting.
If cancer treatment decision making were a triad formed by efficacy, toxicity, and cost, Dr Feinberg, vice president and chief medical officer at Cardinal Health Specialty Solutions, believes that in oncology care, “we’ve been translating the toxicity as the equivalent of quality of life” and giving it the least recognition. He believes clinicians get distracted by the complexity of the myriad quality-of-life measurement scores, which can lead them to often miss the simplest things. Rather, Dr Feinberg suggests, we should ask simple questions, record them continually, and review the impact.
“Quality-of-life is important, but measurement is a problem,” says Dr Kiss, vice president, healthcare transformation, Blue Cross Blue Shield of Florida. The instruments used to measure end-of-life treatment regimens should be better validated, but it is important that they remain “simple, straightforward, and patient friendly.” As to what specific quality-of-life metrics can add meaningful value for palliative care treatment regimens, Dr Kiss mentions the MD Anderson Symptom Inventory (MDASI) and the Optum SF™ Health Surveys, among others, calling them “pretty good” and “pretty well validated.”
Dr Feinberg expresses concern about the complexity of the available tools, the literacy and problem-solving sophistication required by those using them, and whether they are culturally relevant across the board. In addition, Dr Feinberg questions what resources it would take to conduct the measurements accurately and with validity in various palliative care environments, including offices, private practice, or in hospitals. Starting with good ideas, dealing with the flaws that develop, and continuing to address those issues one at a time would lead to some good progress, says Dr Feinberg.
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
The Supreme Court seems likely to reject a challenge to the abortion pill mifepristone; the FDA is inspecting far fewer pharmaceutical companies conducting clinical research; AstraZeneca has sued to block an Arkansas law that it said would unlawfully expand the 340B program to include for profit-pharmacy chains.
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen